Cancer immunotherapy articles within Nature Materials

Featured

  • News & Views |

    Lymphatic vessels within and near to tumours facilitate nanoparticle transport out of tumours, with ramifications in the design and implementation of next-generation clinical cancer nanomedicines.

    • Meghan J. O’Melia
    •  & Susan N. Thomas

  • News & Views |

    An elaborate DNA origami tubular nanodevice encapsulating antigens and adjuvants protects mice from cancer through tumour-specific immunomodulation.

    • Hongjun Li
    •  & Zhen Gu

  • News & Views |

    In situ metabolic labelling and targeted modulation of dendritic cells has been achieved using a hydrogel system in combination with covalent capture of antigens and adjuvants, facilitating improved tumour-specific immune response.

    • Joshua M. Gammon
    •  & Christopher M. Jewell

  • Article |

    A DNA nanodevice vaccine has been developed and utilized to stimulate a tumour-specific cytotoxic T lymphocyte response in vivo, leading to the inhibition of tumour growth as well as prevention of metastasis.

    • Shaoli Liu
    • , Qiao Jiang
    •  & Baoquan Ding

  • Article |

    Dendritic cells concentrated in vivo within a hydrogel have been metabolically tagged with azido groups to enable tracking as well as delivery of antigens, adjuvants and cytokines, thereby facilitating targeted immunomodulation.

    • Hua Wang
    • , Miguel C. Sobral
    •  & David J. Mooney

  • Feature |

    Camille M. Le Gall, Jorieke Weiden, Loek J. Eggermont and Carl G. Figdor provide an overview of immunotherapeutics for cancer treatment that harness dendritic cells, their challenges in clinical use, and approaches employed to enhance their recruitment and activation to promote effective anti-tumour immunity.

    • Camille M. Le Gall
    • , Jorieke Weiden
    •  & Carl G. Figdor

  • Feature |

    Darrell Irvine provides an overview of the recent advances in materials science that have enabled the use of innovative natural and synthetic compounds in vaccine development capable of regulating the potency and safety of new vaccines progressing towards the clinic.

    • Darrell Irvine

  • Feature |

    Tumour heterogeneity and off-target toxicity are current challenges of cancer immunotherapy. Karine Dzhandzhugazyan, Per Guldberg and Alexei Kirkin discuss how epigenetic induction of tumour antigens in antigen-presenting cells may form the basis for multi-target therapies.

    • Karine N. Dzhandzhugazyan
    • , Per Guldberg
    •  & Alexei F. Kirkin

  • Editorial |

    As the interaction of the immune system with the tumour microenvironment becomes increasingly understood, more evidence indicates how immunotherapy can be employed to better eliminate cancers.

  • News & Views |

    A strategy to enhance antigen immunogenicity was developed by adsorption of polyethyleneimine on a mesoporous silica microrod vaccine for the presentation of tumour viruses and neoantigens, demonstrating their ability to drive anti-tumour immunity.

    • Cornelis J. M. Melief

  • Article |

    The sustained release of both hydrophilic and hydrophobic immunomodulators for metastatic melanoma by nanoscale liposomal polymeric gels administered intratumorally or systemically is demonstrated. It is also shown that such a co-delivery approach delays tumour growth and increases the survival of tumour-bearing mice, and that its efficacy results from the activation of both innate and adaptative immune responses.

    • Jason Park
    • , Stephen H. Wrzesinski
    •  & Tarek M. Fahmy

Browse broader subjects

Browse Cancer immunotherapy across other nature.com journals